BC Extra | Jul 24, 2019
Company News

Avalon seeks boost from GE cell therapy manufacturing tech

Avalon partnered with GE Healthcare to use its FlexFactory Cell Therapy platform to standardize, automate and accelerate the production of Avalon's cell therapies, including its lead candidate, a next generation CAR T therapy. While Avalon...
BC Extra | Aug 9, 2016
Company News

Editas, Adverum partner to treat retinal diseases

Editas Medicine Inc. (NASDAQ:EDIT) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) will collaborate to develop gene editing-based treatments for up to five inherited retinal diseases. The deal combines Adverum's next-generation adeno-associated viral (AAV) vectors with Editas' genome...
BC Extra | Feb 2, 2016
Company News

Avalanche acquires Annapurna

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 million new Avalanche shares, worth about $105.6 million based on...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are in the...
BC Week In Review | Sep 7, 2015
Clinical News

AVA-101: Phase IIb discontinued

Avalanche said it will not begin a Phase IIb trial of AVA-101 this half to treat wet AMD after further analyses of data from a Phase IIa trial of the compound in the indication. Instead,...
BioCentury | Aug 24, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/21 cls Avalanche Biotechnologies Inc. (NASDAQ:AAVL) Chardan Capital Gbola Amusa Upgrade Buy (from neutral) 6% $10.62 Amusa upgraded, saying the...
BC Extra | Aug 15, 2015
Company News

Avalanche slides as AVA-101 hits dead end in AMD

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) fell $3.82 (28%) to $10.01 on Friday after it said it will not begin a Phase IIb study this half of gene therapy AVA-101 to treat wet age-related macular degeneration (AMD),...
BioCentury | Jul 27, 2015
Strategy

Rules of competition

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that if the...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Jun 22, 2015
Clinical News

AVA-101: Phase IIa data

Top-line data from a Phase IIa trial in 32 wet AMD patients ages >=55 showed that a single sub-retinal injection of AVA-101 plus Lucentis ranibizumab on day 0 and at week 4 met the primary...
Items per page:
1 - 10 of 27